| __timestamp | Alnylam Pharmaceuticals, Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 165772000 |
| Thursday, January 1, 2015 | 60610000 | 196614000 |
| Friday, January 1, 2016 | 89354000 | 303251000 |
| Sunday, January 1, 2017 | 199365000 | 366406000 |
| Monday, January 1, 2018 | 382359000 | 434407000 |
| Tuesday, January 1, 2019 | 479005000 | 468711000 |
| Wednesday, January 1, 2020 | 588420000 | 516922000 |
| Friday, January 1, 2021 | 620639000 | 739560000 |
| Saturday, January 1, 2022 | 770658000 | 1002140000 |
| Sunday, January 1, 2023 | 795646000 | 1161300000 |
| Monday, January 1, 2024 | 975526000 | 1242157000 |
Unleashing insights
In the competitive landscape of biotechnology, managing operational costs is crucial. Over the past decade, Alnylam Pharmaceuticals and Incyte Corporation have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive expansion and investment in innovation. Incyte, on the other hand, saw a 600% increase, indicating a more measured growth strategy. Notably, in 2023, Incyte's SG&A expenses were about 46% higher than Alnylam's, highlighting its larger scale of operations. These trends underscore the strategic choices each company makes in balancing growth with cost management. As the biotech industry continues to evolve, understanding these financial dynamics offers valuable insights into the operational strategies of leading firms.
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Incyte Corporation
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Incyte Corporation Trends and Insights
Breaking Down SG&A Expenses: Incyte Corporation vs Viatris Inc.
Comparing SG&A Expenses: Incyte Corporation vs Dr. Reddy's Laboratories Limited Trends and Insights
Comparing SG&A Expenses: Incyte Corporation vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Incyte Corporation vs Agios Pharmaceuticals, Inc.